Mast Cell Tumours or MCTs are the most dreaded tumour in veterinary medicine. Though they are easily diagnosed in the consult room, they immediately pose an issue as to grading, staging and treatment. Grade I MCTs, as we know, are usually easily surgically removed and pose a low risk of further metastasis, while high-grade MCTs may require multimodal treatment and careful monitoring. In this episode, we will be reviewing the new grading system for MCTs, as well as treatment advances for high-grade MCTs and reviewing the science on what treatment protocol is going to give us the best outcome for our patients.

Find a transcript of this episode, as well as any papers used in this episode, here: https://bit.ly/42TVjvp

Find an additional flowchart to print and use when making clinical decisions for a diagnosed mast cell tumour here: https://bit.ly/3LWntPG

After the exciting launch of Solensia, the innovative monthly injection for osteoarthritis in cats, the canine version is finally here! Librela, or Beransa as it’s known in Australia, is a monoclonal antibody against Nerve Growth Factor that is used as a monthly injection in dogs. In this podcast, we’ll discuss how it works and how to give it, how safe it is in dogs with other comorbidities, and how effective it is compared to our existing treatments.

Find a transcript of this podcast, as well as a list of references, here.

https://shorturl.at/dIMW5

Leptospirosis is endemic in certain areas such as South-East Asia and South America, but in Australia's New South Wales this disease is making a resurgence after having no cases since 1976. In this podcast, we will review the pathogenesis and clinical signs of leptospirosis both in cats and dogs, look at the distribution of the current outbreak in NSW and what can be done to prevent this disease from becoming endemic, and look at the latest updates on treatment and prognosis.

Find a transcript of this episodes, as well as all figures and references, here: shorturl.at/bewKW

Don't forget to follow us on Facebook and Twitter as well!